RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

One other issue: Some pharma companies, even some of the largest, now have a policy where they cap the number of CNS programs that can be in clinical development at any given time. If a new one is inlicensed, they have to terminate something already inhouse--which means something that they developed themselves, hence there is an internal champion for the program, or one that was previously inlicensed-also championed. We like to think of it as--it would be cheap to acquire the rights to Cortex's compounds. Pharma companies instead calculate how long and how much they would have to spend to take them all the way through clinical testing and regulatory filing--and for many, what program(s) they would have to sacrifice in order to do so.

This makes the decision-making more complex, and to be frank, colored by emotional factors. Companies now like to say they no longer espouse the 'not invented here' bias, but it still plays a role.

NP